Skip to main content

Table 3 PTV indices, dose to the brain and to the contralateral hippocampus

From: Hippocampal sparing radiotherapy for glioblastoma patients: a planning study using volumetric modulated arc therapy

  3D-CRT/median (range) VMAT/median (range) p-value
PTV indices
V 95 % 0.88 (0.79–0.97) 0.91 (0.79–0.99) NS (p = 0.05)
V 100 % 0.53 (0.17–0.75) 0.56 (0.38–0.84) NS (p = 0.18)
 HI 0.18 (0.09–0.24) 0.15 (0.06–0.21) p < 0.01
CI 95 % 0.70 (0.32–0.78) 0.80 (0.75–0.91) p < 0.01
CI 100 % 0.48 (0.15–0.70) 0.55 (0.36–0.78) NS (p = 0.09)
Brain
Mean dose (Gy) 35.7 (23.7–45.0) 34.0 (24.2–40.3) p < 0.01
V 12Gy (%) 89.6 (53.5–98.5) 89.2 (70.7–97.3) p < 0.01
V 30Gy (%) 58.7 (31.3–81.0) 48.2 (27.2–62.4) p < 0.01
V 45Gy (%) 40.0 (19.0–56.3) 32.9 (17.7–47.7) p < 0.01
Contralateral hippocampus
Mean dose (Gy) 33.1 (12.1–50.1) 14.7 (8.1–40.3) p < 0.01
Mean EQD2 (Gy) 25.7 (7.3–46.0) 9.2 (4.6–33.7) p < 0.01
Max dose (Gy) 39.6 (30.1–59.9) 26.7 (12.6–62.3) p < 0.01
Max EQD2 (Gy) 32.9 (22.6–59.9) 19.3 (7.6–63.5) p < 0.01
gEUD (Gy) 36.3 (24.3–56.1) 23.1 (10.8–56.0) p < 0.01
V 10Gy/5.8Gy(EQD2) (%) 100. (44.3–100.) 100. (14.2–100.) p < 0.01
V 15Gy/9.4Gy(EQD2) (%) 100. (14.4–100.) 32.3 (0.0–100.) p < 0.01
V 20Gy/13.3Gy(EQD2) (%) 100. (8.3–100.) 12.6 (0.0–83.0) p < 0.01
V 30Gy/22.5Gy(EQD2) (%) 70.5 (2.2–100.) 3.4 (0.0–69.0) p < 0.01
V 40Gy/33.3Gy(EQD2) (%) 1.4 (0.0–100.) 0.4 (0.0–61.3) p < 0.01